Deferiprone

Generic Name: Deferiprone

Brand Names: Ferriprox, Deferiprone Lipomed

Drug Type: Small Molecule

Chemical Formula: C_₇H_₉NO_₂

CAS Number: 30652-11-0

Unique Ingredient Identifier: 2BTY8KH53L

Background: Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011.

Indication: Deferiprone is indicated in thalassemia syndromes when first line chelation agents are not adequate to treat transfusional iron overload.

Associated Conditions: Transfusional Iron Overload

Associated Therapies: -

Clinical Trials

An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients

Phase 2

Conditions: Beta Thalassemia Major

Interventions: Drug: Deferiprone

First Posted Date: 2014-06-25

Last Posted Date: 2015-01-14

Lead Sponsor: Ain Shams University

Target Recruit Count: 64

Registration Number: NCT02173951

Locations: 🇪🇬
Pediatric Hematology clinic, Ain Shams University, Cairo, Egypt

Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients

Phase 2

Completed

Conditions: ALS (Amyotrophic Lateral Sclerosis)
Iron Overload

Interventions: Drug: Deferiprone

First Posted Date: 2014-06-16

Last Posted Date: 2017-03-09

Lead Sponsor: University Hospital, Lille

Target Recruit Count: 23

Registration Number: NCT02164253

Locations: 🇫🇷
Hôpital Roger Salengro, CHRU de Lille, Lille, France

Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias

Phase 4

Terminated

Conditions: Iron Overload
Other Anemias
Sickle Cell Disease

Interventions: Drug: Deferiprone
Drug: Deferoxamine

First Posted Date: 2014-01-22

Last Posted Date: 2021-08-10

Lead Sponsor: ApoPharma

Target Recruit Count: 230

Registration Number: NCT02041299

Locations: 🇺🇸
Children's Hospital, New Orleans, Louisiana, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇪🇬
Ains Shams University, Cairo, Egypt

and more 30 locations

A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Deferiprone
Drug: Placebo

First Posted Date: 2013-11-21

Last Posted Date: 2014-12-23

Lead Sponsor: ApoPharma

Target Recruit Count: 64

Registration Number: NCT01989455

Locations: 🇨🇦
Algorithme Pharma Inc., Mont-Royal, Quebec, Canada

Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects

Phase 4

Completed

Conditions: Prolonged QTc Interval

Interventions: Drug: Deferiprone
Drug: deferiprone matching placebo tablets
Drug: moxifloxacin
Drug: placebo

First Posted Date: 2013-05-23

Last Posted Date: 2014-11-12

Lead Sponsor: ApoPharma

Target Recruit Count: 50

Registration Number: NCT01860703

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients

Phase 3

Completed

Conditions: Chronic Iron Overload

Interventions: Drug: Deferiprone
Drug: Deferasirox

First Posted Date: 2013-04-05

Last Posted Date: 2021-05-04

Lead Sponsor: Consorzio per Valutazioni Biologiche e Farmacologiche

Target Recruit Count: 435

Registration Number: NCT01825512

Locations: 🇪🇬
Cairo University Faculty of Medicine, Cairo, Egypt
🇪🇬
Zagazig University Hospitals, Zagazig, Egypt
🇦🇱
Hospital 'Ihsan Çabej', Lushnjë, Albania

and more 19 locations

An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment

Phase 4

Completed

Conditions: Renal Impairment

Interventions: Drug: Deferiprone

First Posted Date: 2013-01-18

Last Posted Date: 2014-08-26

Lead Sponsor: ApoPharma

Target Recruit Count: 32

Registration Number: NCT01770652

Locations: 🇨🇦
Algorithme Pharma Inc., Mount-Royal, Quebec, Canada
🇨🇦
Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada

Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent

Phase 3

Withdrawn

Conditions: Acute Kidney Injury

Interventions: Drug: Placebo
Drug: deferiprone

First Posted Date: 2011-07-12

Last Posted Date: 2020-08-24

Lead Sponsor: CorMedix

Registration Number: NCT01391520

Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease

Phase 2

Completed

Conditions: Parkinson's Disease

Interventions: Drug: placebo
Drug: deferiprone

First Posted Date: 2009-07-22

Last Posted Date: 2012-09-03

Lead Sponsor: University Hospital, Lille

Target Recruit Count: 40

Registration Number: NCT00943748

Locations: 🇫🇷
Service de Neurologie, Clinique Neurologique, EA 2683, IFR 114, Lille, France

Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)

Phase 2

Active, not recruiting

Conditions: Neurodegenerative Disease
Iron Overload

Interventions: Drug: Deferiprone

First Posted Date: 2009-05-22

Last Posted Date: 2023-02-09

Lead Sponsor: Ente Ospedaliero Ospedali Galliera

Target Recruit Count: 20

Registration Number: NCT00907283

Locations: 🇮🇹
Centre of Microcitemia and Congenital Anemias, Galliera Hospital, Genoa, Italy
🇮🇹
Neurological Pathology Department, Brotzu Hospital, Cagliari, Italy
🇮🇹
Clinic of Neurology, University of Genoa, Genoa, Italy

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy